Completed PHASE3 INTERVENTIONAL 2-arm NCT04294251

Efficacy and Safety of DWP450 in Subjects With Benign Masseteric Hypertrophy

A Double-blind, Randomized, Placebo-controlled, Multi-center, Phase Ⅲ Study to Evaluate the Efficacy and Safety of NABOTA® in Subjects With Benign Masseteric Hypertrophy

Sponsor: Daewoong Pharmaceutical Co. LTD.

Conditions Benign Masseteric Hypertrophy

Interventions DWP450 Placebo

Updated 7 times since 2020 Last updated: Nov 28, 2022 Started: Mar 4, 2020 Primary completion: Jan 7, 2021 Completion: Aug 10, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Benign Masseteric Hypertrophy and is currently completed. Daewoong Pharmaceutical Co. LTD. leads this study, which shows 7 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Dec 2022 — Jul 2024 [monthly]

Completed PHASE3

Status: Unknown Status → Completed
Apr 2022 — Dec 2022 [monthly]

Unknown Status PHASE3

Status: Not Yet Recruiting → Unknown Status

▶ Show 2 earlier versions

Jan 2021 — Apr 2022 [monthly]

Not Yet Recruiting PHASE3
Apr 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE3

First recorded

Mar 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Daewoong Pharmaceutical Co. LTD.

Data source: Daewoong Pharmaceutical Co. LTD.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea